Sayed Yousef Mojtahedi
1,2 
, Maryam Ghodsi
3, Paniz Pourpashang
4* 1 Department of Pediatric Nephrology, Tehran University of Medical Sciences, Tehran, Iran
2 Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Pediatrics, School of Medicine Bahrami Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Pediatric Nephrology, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Montelukast holds significant promise as a renoprotective agent, especially in early-stage kidney injuries. Its multifaceted mechanisms—ranging from anti-inflammatory and antioxidant actions to neutrophil inhibition—underscore its potential utility in clinical settings. Montelukast should not be used in patients with a known hypersensitivity to the drug or its components. Caution is advised for individuals with a history of psychiatric disorders or those who have phenylketonuria (PKU), as some formulations contain phenylalanine.
Implication for health policy/practice/research/medical education:
Montelukast as a leukotriene receptor antagonist, with several protective effects against kidney damage caused by chemotherapy. Montelukast reduces inflammation in renal tissues, which is crucial during chemotherapy-induced nephrotoxicity.
Please cite this paper as: Mojtahedi SY, Ghodsi M, Pourpashang P. Renoprotective efficacy of montelukast; an overview on recent advancements. J Nephropharmacol. 2025;14(1):e12759. DOI: 10.34172/npj.2025.12759.